2023年4月13日

共同Jeito资本,RA的资本管理和新生,融资轮也参与Bpifrance等从现有投资者通过其InnoBio 2基金,施罗德资本,BB Pureos Bioventures。Alentis疗法打算使用资金的二期和一期项目领导临床实验的啤酒产品。F02和啤酒。C04, first-in-class anti-Claudin-1 (CLDN1)抗体,分别。啤酒。F02正在开发先进的治疗肾、肺和肝纤维化同时啤酒。C04是一个潜在的治疗目标CLDN1-positive肿瘤。一轮融资所得也将用于CLDN1的发展平台工程师CLDN1抗体药物配合(ADC)和双特异性抗体。沉默的效应函数,啤酒。F02设计针对硬ECM的纤维组织和器官。啤酒。C04效应函数,直接目标癌症而沉默CLDN1-mediated致癌信号。 It is designed to open up stiff extracellular matrix (ECM) in tumours with immune evasion mechanisms. Alentis Therapeutics CEO Dr Roberto Iacone said: “There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programmes. “We can now aggressively develop CLDN1 biology in oncology and continue with the recruitment of our organ fibrosis trials while advancing our ADC and bi-specific antibodies.” The latest financing round comes after the company received $67m in Series B funding in June 2021. Share this article